10-Q 1 c94998e10vq.txt QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2005 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD _________ to _________. COMMISSION FILE NUMBER: 000-31745 THIRD WAVE TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) DELAWARE 39-1791034 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) 502 S. ROSA ROAD, MADISON, WI 53719 (Address of principal executive offices) (Zip Code) (888) 898-2357 (Registrant's telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check whether the Registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes [X] No [ ] The number of shares outstanding of the registrant's Common Stock, $.001 par value, as of March 31, 2005, was 41,154,491. THIRD WAVE TECHNOLOGIES, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2005 TABLE OF CONTENTS
PAGE NO. PART I FINANCIAL INFORMATION............................................................................................ 3 Item 1. Financial Statements.......................................................................................... 3 Consolidated Balance Sheets as of March 31, 2005 and December 31, 2004............................................... 3 Consolidated Statements of Operations for the three months ended March 31, 2005 and 2004............................. 4 Consolidated Statements of Cash Flows for the three months ended March 31, 2005 and 2004............................. 5 Notes to Consolidated Financial Statements........................................................................... 6 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations......................... 9 Item 3. Quantitative and Qualitative Disclosures About Market Risk.................................................... 12 Item 4. Controls and Procedures....................................................................................... 12 PART II OTHER INFORMATION............................................................................................... 14 Item 1. Legal Proceedings............................................................................................. 14 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds................................................... 14 Item 3. Defaults Upon Senior Securities............................................................................... 14 Item 4. Submission Of Matters To A Vote Of Security Holders........................................................... 14 Item 5. Other Information............................................................................................. 14 Item 6. Exhibits...................................................................................................... 14 SIGNATURES.............................................................................................................. 16 EXHIBITS................................................................................................................ 17
2 PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS THIRD WAVE TECHNOLOGIES, INC. Consolidated Balance Sheets
MARCH 31, DECEMBER 31, 2005 2004 UNAUDITED ASSETS Current assets: Cash and cash equivalents $ 53,460,740 $ 55,619,981 Short-term investments 11,070,000 11,070,000 Receivables, net of allowance for doubtful accounts of $185,000 and $300,000, respectively 4,501,515 5,784,679 Inventories 1,389,075 1,236,392 Prepaid expenses and other 679,558 260,316 ------------- ------------- Total current assets 71,100,888 73,971,368 Equipment and leasehold improvements: Machinery and equipment 15,907,379 15,832,489 Leasehold improvements 2,283,792 2,277,604 ------------- ------------- 18,191,171 18,110,093 Less accumulated depreciation 12,581,644 12,139,423 ------------- ------------- 5,609,527 5,970,670 Assets held for sale 269,000 269,000 Intangible assets, net of accumulated amortization 3,770,184 4,146,372 Indefinite lived intangible assets 1,007,411 1,007,411 Goodwill 489,873 489,873 Other long term assets 2,086,667 2,212,935 ------------- ------------- Total assets $ 84,333,550 $ 88,067,629 ============= ============= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 7,479,046 $ 6,519,005 Accrued payroll and related liabilities 2,130,286 2,873,506 Other accrued liabilities 2,037,426 1,867,361 Deferred revenue 314,333 129,530 Capital lease obligation due within one year 101,378 66,867 Long-term debt due within one year 9,615,428 9,614,127 ------------- ------------- Total current liabilities 21,677,897 21,070,396 Long-term debt 305,650 335,069 Deferred revenue - long term 227,171 254,434 Capital lease obligations - long term 196,315 151,885 Other liabilities 3,910,674 3,520,948 Shareholders' equity: Participating preferred stock, Series A, $.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding 0 0 Common stock, $.001 par value, 100,000,000 shares authorized, 41,154,491 and 41,102,764 shares issued and outstanding, respectively 41,154 41,103 Additional paid-in capital 198,343,828 198,990,162 Unearned stock compensation (205,671) (554,293) Foreign currency translation adjustment 31,095 31,949 Accumulated deficit (140,194,563) (135,774,024) ------------- ------------- Total shareholders' equity 58,015,843 62,734,897 ------------- ------------- Total liabilities and shareholders' equity $ 84,333,550 $ 88,067,629 ============= =============
See accompanying notes to financial statements. 3 THIRD WAVE TECHNOLOGIES, INC. Consolidated Statements of Operations (Unaudited)
THREE MONTHS ENDED --------------------------- MARCH 31, --------------------------- 2005 2004 ------------ ------------ Revenues: Product sales $ 6,914,276 $ 15,214,638 License and royalty revenue 93,083 40,641 Grant revenue 118,884 20,330 ------------ ------------ Total revenues 7,126,243 15,275,609 ------------ ------------ Operating expenses: Cost of goods sold Product cost of goods sold 1,538,676 3,599,760 Intangible and long-term asset amortization 461,395 571,096 ------------ ------------ Total cost of goods sold 2,000,071 4,170,856 Research and development 2,465,380 2,672,876 Selling and marketing 3,364,493 2,624,772 General and administrative 3,779,264 2,357,391 ------------ ------------ Total operating expense 11,609,208 11,825,895 ------------ ------------ Income (loss) from operations (4,482,965) 3,449,714 Other income (expense): Interest income 347,000 127,190 Interest expense (89,387) (56,994) Other (195,187) (671,486) ------------ ------------ Total other income (expense) 62,426 (601,290) ------------ ------------ Net income (loss) $ (4,420,539) $ 2,848,424 ============ ============ Net income (loss) per share - basic $ (0.11) $ 0.07 ============ ============ Net income (loss) per share - diluted $ (0.11) $ 0.07 ============ ============ Weighted average shares outstanding Basic 41,123,521 40,079,040 ============ ============ Diluted 41,123,521 41,566,020 ============ ============
See accompanying notes to financial statements. 4 THIRD WAVE TECHNOLOGIES, INC. Consolidated Statements of Cash Flows (Unaudited)
THREE MONTHS ENDED MARCH 31, --------------------------- 2005 2004 ------------ ------------ OPERATING ACTIVITIES: Net income (loss) $ (4,420,539) $ 2,848,424 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 544,320 788,401 Amortization of intangible assets 376,188 376,188 Noncash stock compensation (414,464) 232,561 Loss on disposal of equipment 8,696 18,474 Changes in operating assets and liabilities: Receivables 1,282,310 (4,122,350) Inventories (152,683) (1,633,800) Prepaid expenses and other assets (378,181) 237,515 Accounts payable 960,041 4,024,998 Accrued expenses and other liabilities (183,429) (1,076,723) Deferred revenue 157,540 49,740 ------------ ------------ Net cash provided by (used in) operating activities (2,220,201) 1,743,428 INVESTING ACTIVITIES: Purchases of equipment and leasehold improvements (10,170) (49,290) ------------ ------------ Net cash used in investing activities (10,170) (49,290) FINANCING ACTIVITIES: Payments on long-term debt (28,118) 0 Payments on capital lease obligations (17,555) 0 Proceeds from common stock, net 116,803 379,214 ------------ ------------ Net cash provided by financing activities 71,130 379,214 ------------ ------------ Net increase (decrease) in cash and cash equivalents (2,159,241) 2,073,352 Cash and cash equivalents at beginning of period 55,619,981 47,015,746 ------------ ------------ Cash and cash equivalents at end of period $ 53,460,740 $ 49,089,098 ============ ============
See accompanying notes to financial statements. 5 THIRD WAVE TECHNOLOGIES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS March 31, 2005 (unaudited) (1) Basis of Presentation The accompanying unaudited consolidated financial statements of Third Wave Technologies, Inc. have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results that may be expected for the year ending December 31, 2005. The balance sheet at December 31, 2004 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. The accompanying unaudited consolidated financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in our Form 10-K for the fiscal year ended December 31, 2004 filed with the Securities and Exchange Commission. (2) Net Income (Loss) Per Share In accordance with accounting principles generally accepted in the United States, basic net income (loss) per share has been computed using the weighted-average number of shares of common stock outstanding during the respective periods. Diluted net income (loss) per share takes into account the weighted average shares from options that could potentially dilute basic net income per share in the future. Shares associated with stock options are excluded for the three months ended March 31, 2005 because they are anti-dilutive. The following table presents the calculation of basic and diluted net income (loss) per share:
THREE MONTHS ENDED MARCH 31, --------------------------- 2005 2004 ------------ ------------ Numerator: Net income (loss) $ (4,420,539) $ 2,848,424 ============ ============ Denominator: Weighted average shares outstanding - basic 41,123,521 40,079,040 Dilutive securities - stock options N/A 1,486,980 ------------ ------------ Weighted average shares outstanding - diluted 41,123,521 41,566,020 Basic net income (loss) per share $ (0.11) $ 0.07 Dilutive net income (loss) per share $ (0.11) $ 0.07
(3) Stock-Based Compensation Third Wave has stock-based employee compensation plans. Statement of Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based Compensation", encourages, but does not require companies to record compensation cost for stock-based employee compensation plans at fair value. We have chosen to continue using the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations, in accounting for our stock option plans. 6 Had compensation cost been determined based upon the fair value at the grant date for awards under the plans based on the provisions of SFAS No. 123, our SFAS No. 123 pro forma net income (loss) and net income (loss) per share would have been as follows:
THREE MONTHS ENDED MARCH 31, ----------------------------- 2005 2004 ------------- ------------- Net income (loss), as reported $ (4,420,539) $ 2,848,424 Add: Stock based compensation, as reported (414,464) 232,561 Less: Stock-based compensation, using fair value method (1,064,014) (1,053,943) ------------- ------------- Pro forma net income (loss) $ (5,899,017) $ 2,027,042 Net income (loss) per share, basic, as reported $ (0.11) $ 0.07 Net income (loss) per share, diluted, as reported $ (0.11) $ 0.07 Pro forma net income (loss) per share, basic $ (0.14) $ 0.05 Pro forma net income (loss) per share, diluted $ (0.14) $ 0.05
As described in Note 2 of Notes to Consolidated Financial Statements in our Form 10-K for the year ended December 31, 2004, the Financial Accounting Standards Board recently issued SFAS No. 123 (revised 2004), "Share-Based Payment", which is a revision of SFAS No. 123. The Company expects to adopt SFAS No. 123(R) on January 1, 2006. (4) Inventories Inventories, consisting mostly of raw materials, are carried at the lower of cost or market using the first-in, first-out (FIFO) method for determining cost. Inventories consist of the following:
MARCH 31, DECEMBER 31, 2005 2004 ----------- ----------- Raw materials $ 1,471,024 $ 1,318,771 Finished goods and work in process 698,051 567,621 Reserve for excess and obsolete inventory (780,000) (650,000) ----------- ----------- Total inventories $ 1,389,075 $ 1,236,392 =========== ===========
(5) Stock Compensation Included in operating expenses are the following stock compensation charges, net of reversals related to terminated employees:
THREE MONTHS ENDED MARCH 31, --------------------- 2005 2004 --------- --------- Cost of goods sold $ (5,749) $ 5,082 Research and development (259,850) 78,335 Selling and marketing 29,708 68,001 General and administrative (178,573) 81,143 --------- --------- Total stock compensation $(414,464) $ 232,561 --------- ---------
(6) Comprehensive Income (Loss) The components of comprehensive income (loss) are as follows:
THREE MONTHS ENDED MARCH 31, ------------------------- 2005 2004 ----------- ----------- Net income (loss) $(4,420,539) $ 2,848,424 Other comprehensive income (loss): Foreign currency translation adjustments (854) 1,350 ----------- ----------- Comprehensive income (loss) $(4,421,393) $ 2,849,774 =========== ===========
(7) Derivative Instruments We sell products in a number of countries throughout the world. In the quarters ending March 31, 2005 and 2004, we sold certain products with the resulting accounts receivable denominated in Japanese Yen. Simultaneous with such sales and purchase order 7 commitments, we purchased foreign currency forward contracts to manage the risk associated with foreign currency collections in the normal course of business. These derivative instruments have maturities of less than one year and are intended to offset the effect of transaction gains and losses, which arise when collections in a foreign currency are received after the asset is generated. There were no contracts outstanding at March 31, 2005. The changes in the fair value of the derivatives and the loss or gain on the hedged asset relating to the risk being hedged are recorded in earnings. (8) Amortizable Intangible Assets Amortizable intangible assets consist of the following:
MARCH 31, 2005 DECEMBER 31, 2004 ------------------------- ------------------------- GROSS GROSS CARRYING ACCUMULATED CARRYING ACCUMULATED AMOUNT AMORTIZATION AMOUNT AMORTIZATION ----------- ------------- ----------- ------------ Costs of settling patent litigation $10,533,248 $ 6,763,064 $10,533,248 $ 6,386,876 Reacquired marketing and distribution rights 2,211,111 2,211,111 2,211,111 2,211,111 Customer agreements 38,000 38,000 38,000 38,000 ----------- ------------ ----------- ------------ Total $12,782,359 $ 9,012,175 $12,782,359 $ 8,635,987 =========== ============ =========== ============
(9) Restructuring and Impairment of Long Lived Assets During the third quarter of 2002, we announced a restructuring plan designed to simplify product development and manufacturing operations and reduce operating expenses. The restructuring charges recorded were determined based upon plans submitted by the Company's management and approved by the Board of Directors using information available at the time. The restructuring charge included $2.5 million for the consolidation of facilities, $500,000 for prepayment penalties mainly under capital lease arrangements, an impairment charge of $7.2 million for abandoned leasehold improvements and equipment to be sold and $900,000 of other costs related to the restructuring. The Company also recorded a $1.1 million charge within cost of goods sold related to inventory that was considered obsolete based upon the restructuring plan. The facilities charge contained estimates based on the Company's potential to sublease a portion of its corporate office. The Company has offered the corporate office space for sublease, but has been unable to sublease the space. Accordingly, the Company decreased its estimate of the amount of sublease income it expects to receive. The estimated lease and operating expenses were also reduced, based on a portion of the office space being utilized. The following table shows the changes in the restructuring accrual since December 31, 2004. The remaining restructuring balance of $1.1 million is for rent payments on a non-cancelable lease, net of estimated sublease income, which will continue to be paid over the lease term through 2011. The current portion of the accrual is included in other accrued liabilities on the balance sheets and the remainder is included in other long-term liabilities. Accrued restructuring balance at December 31, 2004 $ 1,116,848 Payments made (38,638) ----------- Accrued restructuring balance at March 31, 2005 $ 1,078,210 -----------
(10) Reclassifications Certain reclassifications have been made to the 2004 financial statements to conform to the 2005 presentation. 8 THIRD WAVE TECHNOLOGIES, INC. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Management's Discussion and Analysis of Financial Condition and Results of Operations as of March 31, 2005 and for the three months ended March 31, 2005 and 2004 should be read in conjunction with our Form 10-K for the fiscal year ended December 31, 2004 filed with the Securities and Exchange Commission. In this Form 10-Q, the terms "we," "us," "our," "Company," and "Third Wave" each refer to Third Wave Technologies, Inc. The following discussion of our financial condition and results of our operations should be read in conjunction with our Financial Statements, including the Notes thereto, included elsewhere in this Form 10-Q. This Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. For a more detailed discussion of such forward-looking statements and the potential risks and uncertainties that may affect their accuracy, see the "Forward-Looking Statements" section of this Form 10-Q. OVERVIEW Third Wave Technologies, Inc. is a leading molecular diagnostics company. We believe our proprietary Invader(R) chemistry, a novel, proprietary molecular chemistry, is easier to use, more accurate and cost-effective, and enables higher testing throughput. These and other advantages conferred by our chemistry are enabling us to provide clinicians and researchers with superior molecular solutions. More than 110 clinical laboratory customers are using Third Wave's molecular diagnostic reagents. Other customers include pharmaceutical and biotechnology companies, academic research centers and major health care providers. Third Wave markets a growing number of products, including analyte specific reagents (ASRs). These ASRs allow certified clinical reference laboratories to create assays to perform hepatitis C virus genotyping, to screen for cystic fibrosis and other inherited disorders, and to test for the Factor V Leiden and a host of other mutations associated with predisposition to cardiovascular and other diseases. The Company has developed or plans to develop a menu of molecular diagnostic products for clinical applications that include genetic testing, pharmacogenetics, oncology/chromosomal analysis, and infectious disease/women's health. The Company also has a number of other Invader(R) products including those for research, agricultural and other applications. Our financial results may vary significantly from quarter to quarter due to fluctuations in the demand for our products, timing of new product introductions and deliveries made during the quarter, the timing of research, development and grant revenues, and increases in spending, including expenses related to our product development. CRITICAL ACCOUNTING POLICIES Management's discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. We review the accounting policies we use in reporting our financial results on a regular basis. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, inventories, equipment and leasehold improvements and intangible assets. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Results may differ from these estimates due to actual outcomes being different from those on which we based our assumptions. These estimates and judgments are reviewed by management on an ongoing basis, and by the Audit Committee at the end of each quarter prior to the public release of our financial results. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements. RESTRUCTURING AND OTHER CHARGES. The restructuring and other charges resulting from the restructuring plan in the third quarter of 2002 has been recorded in accordance with EITF Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)", Staff Accounting Bulletin No. 100, "Restructuring and Impairment Charges," and Statement of Financial Accounting Standards (SFAS) No. 144, "Accounting for the Impairment or Disposal of 9 Long-Lived Assets." The restructuring charge was comprised primarily of costs to consolidate facilities, impairment charges for abandoned leasehold improvements and equipment to be sold or abandoned, prepayment penalties related mainly to capital lease obligations on equipment to be sold or abandoned, and other costs related to the restructuring. The remaining accrued restructuring balance is for rent payments on a non-cancelable lease, net of estimated sublease income. In calculating the cost to consolidate the facilities, we estimated the future lease and operating costs to be paid until the leases are terminated and the amount, if any, of sublease receipts for each location. This required us to estimate the timing and costs of each lease to be terminated, the amount of operating costs, and the timing and rate at which we might be able to sublease the site. To form our estimates for these costs, we performed an assessment of the affected facilities and considered the current market conditions for each site. Our assumptions on the lease termination payments, operating costs until terminated, and the offsetting sublease receipts may turn out to be incorrect and our actual cost may be materially different from our estimates. LONG-LIVED ASSETS--IMPAIRMENT Equipment, leasehold improvements and amortizable identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For assets held and used, if the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and carrying value of the asset or group of assets. For assets removed from service and held for sale, we estimate the fair market value of such assets and record an adjustment if fair value less costs to sell is lower than carrying value. Goodwill and intangible assets deemed to have indefinite lives are not amortized, but are subject to annual impairment tests under SFAS No. 142, "Goodwill and Other Intangible Assets." The annual impairment tests are completed in the quarter ended September 30. DERIVATIVE INSTRUMENTS We sell products in a number of countries throughout the world. During 2005 and 2004, we sold certain products with the resulting accounts receivable denominated in Japanese Yen. Simultaneous with such sales and purchase order commitments, we purchased foreign currency forward contracts to manage the risk associated with collections of receivables denominated in foreign currencies in the normal course of business. These derivative instruments have maturities of less than one year and are intended to offset the effect of transaction gains and losses. There were no contracts outstanding at March 31, 2005. The changes in the fair value of the derivatives and the loss or gain on the hedged asset relating to the risk being hedged are recorded in earnings. INVENTORIES--SLOW MOVING AND OBSOLESCENCE Significant management judgment is required to determine the reserve for obsolete or excess inventory. Inventory on hand may exceed future demand either because of process improvements or technology advancements, the amount on hand is more than can be used to meet future need, or estimates of shelf lives may change. We currently consider all inventory that we expect will have no activity within one year as well as any additional specifically identified inventory to be subject to a provision for excess inventory. We also provide for the total value of inventories that we determine to be obsolete based on criteria such as changing manufacturing processes and technologies. At March 31, 2005, our inventory reserves were $0.8 million, or 36% of our $2.2 million total gross inventories. RESULTS OF OPERATIONS Three Months Ended March 31, 2005 and 2004 REVENUES. Revenues for the three months ended March 31, 2005 of $7.1 million represented a decrease of $8.2 million, compared to revenues of $15.3 million for the corresponding period of 2004. Product revenues decreased to $6.9 million for the quarter ended March 31, 2005, from $15.2 million in the quarter ended March 31, 2004. The decrease in product sales during the three months ending March 31, 2005 was due to a decline in orders from a major Japanese research institute. We expect our molecular diagnostic revenues to increase throughout 2005, as we continue to launch new products. 10 Significant Customer. We generated $3.1 million, or 44% of our revenues, from sales to a major Japanese research institute for use by several end-users during the three months ended March 31, 2005. We believe this customer will continue to purchase Company products, however, the timing and total of such purchases will be influenced by the Japanese government funding process, which is unpredictable. COST OF GOODS SOLD. Cost of goods sold consists of materials used in the manufacture of product, depreciation on manufacturing capital equipment, salaries and related expenses for management and personnel associated with our manufacturing and quality control departments and amortization of licenses and settlement fees. For the three months ended March 31, 2005, cost of goods sold decreased to $2.0 million, compared to $4.2 million for the corresponding period of 2004. The decrease in the three month period was primarily due to the decrease in sales volume. Cost of goods sold as a percentage of revenue remained relatively flat for the three months ended March 31, 2005, compared to 2004. We expect gross margin to improve as molecular diagnostic revenues increase. RESEARCH AND DEVELOPMENT EXPENSES. Research and development expenses consist primarily of salaries and related personnel costs, material costs for assays and product development, fees paid to consultants, depreciation and facilities costs and other expenses related to the design, development, testing and enhancement of our products and acquisition of technologies used or to be used in our products. Research and development costs are expensed as they are incurred. Research and development expenses for the three months ended March 31, 2005, were $2.5 million, compared to $2.7 million for the three months ended March 31, 2004. The research and development expenses remained relatively constant for the comparative periods. We will continue to invest in research and development, and expenditures in this area may increase as we expand our product development efforts. SELLING AND MARKETING EXPENSES. Selling and marketing expenses consist primarily of salaries and related personnel costs for our sales and marketing management and field sales force, commissions, office support and related costs, and travel and entertainment. Selling and marketing expenses for the three months ended March 31, 2005, were $3.4 million, an increase of $0.8 million, compared to $2.6 million for the corresponding period of 2004. The increase in the three months ended March 31, 2005 was due to an increase in personnel related expenses compared to the same period in 2004. With the expansion of our clinical sales force, we anticipate selling and marketing expenses to continue to be at or above expense levels in 2004. GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative expenses consist primarily of salaries and related expenses for executive, finance and other administrative personnel, legal and professional fees, office support and depreciation. General and administrative expenses increased to $3.8 million in the three months ended March 31, 2005, from $2.4 million for the corresponding period in 2004. The increase in the three months ended March 31, 2005, was due to an increase in personnel related expenses, legal expenses related to litigation, and consulting fees compared to the corresponding period of 2004. The Company anticipates increased legal expenses as a result of its patent infringement lawsuit against Stratagene. As the Company moves towards consideration of FDA cleared or approved products, there will be increased expenses attributed to those activities. INTEREST INCOME. Interest income for the three months ended March 31, 2005 was $0.3 million, compared to $0.1 million for the corresponding period of 2004. The increase in the three months ended March 31, 2005 was due to higher interest rates compared to 2004. INTEREST EXPENSE. Interest expense for the three months ended March 31, 2005 and 2004 was approximately $0.1 million. OTHER INCOME (EXPENSE): Other expense for the three months ended March 31, 2005 was $0.2 million, compared to other expense of $0.7 million for the three months ended March 31, 2004. The decrease in other expense was primarily due to the adjustment of foreign currency contracts and the related hedged asset to fair value at March 31, 2004. LIQUIDITY AND CAPITAL RESOURCES Since our inception, we have financed our operations primarily through private placements of equity securities, research grants from federal and state government agencies, payments from strategic collaborators, equipment loans, capital leases, sale of products, a convertible note and an initial public offering. As of March 31, 2005, we had cash and cash equivalents and short-term investments of $64.5 million. Net cash utilized by operations for the three months ended March 31, 2005 was $2.2 million, compared to net cash provided by operations of $1.7 million in the corresponding period in 2004. The decrease in cash from operations was due to an increase in operating losses. 11 Net cash used in investing activities for the three months ended March 31, 2005 was $10,170, compared to net cash used by investing of $49,290, in the same period in 2004. The cash utilized during both comparative periods resulted from the purchase of equipment. Net cash provided by financing activities was $0.1 million in the three months ended March 31, 2005, compared to $0.4 million in the three months ended March 31, 2004. Cash provided by financing activities for the period ended March 31, 2005 consisted of proceeds from the sale of common stock of $0.1 million compared to $0.4 million in the corresponding period of 2004. There have been no significant changes in our contractual obligations since December 31, 2004. As of December 31, 2004 and March 31, 2005, a valuation allowance equal to 100% of our net deferred tax assets had been recognized since our future realization is not assured. At December 31, 2004, we had federal and state net operating loss carryforwards of approximately $113 million. The net operating loss carryforwards will expire at various dates beginning in 2008, if not utilized. Utilization of the net operating losses and credits to offset future taxable income may be subject to an annual limitation due to the change of ownership provisions of federal tax laws and similar state provisions as a result of the initial public offering in February 2001. We cannot assure you that our business or operations will not change in a manner that would consume available resources more rapidly than anticipated. We also cannot assure you that we will not require substantial additional funding before we can achieve profitable operations. Our capital requirements depend on numerous factors, including the following: - our progress with our research and development programs; - our level of success in selling our products and technologies; - our ability to establish and maintain successful collaborative relationships; - the costs we incur in enforcing and defending our patent claims and other intellectual property rights; and - the timing of purchases of additional capital. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Our exposure to market risk is currently confined to changes in foreign exchange and interest rates. The securities in our investment portfolio are not leveraged and, due to their short-term nature, are subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Due to the short-term maturities of our investments, we do not believe that an increase in market rates would have any negative impact on the realized value of our investment portfolio. To reduce foreign exchange risk, we selectively use financial instruments. Our earnings are affected by fluctuations in the value of the U.S. dollar against foreign currencies as a result of the sales of our products in foreign markets. Forward foreign exchange contracts are used to hedge against the effects of such fluctuations. Our policy prohibits the trading of financial instruments for profit. A discussion of our accounting policies for derivative financial instruments is included in the notes to the annual financial statements. ITEM 4. CONTROLS AND PROCEDURES As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, conducted an evaluation as of the end of the period covered by this report, of the effectiveness of the Company's disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Based on that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of the end of the period covered by this report. As required by Rule 13a-15(d) under the Securities Exchange Act of 1934 the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, also conducted an evaluation of the company's internal control over financial reporting to determine whether any changes occurred during the quarter covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. Based on that evaluation, there has been no such change during the quarter covered by this report. 12 FORWARD-LOOKING STATEMENTS This Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. When used in this Form 10-Q the words "believe," "anticipates," "intends," "plans," "estimates," and similar expressions are forward-looking statements. Such forward-looking statements contained in this Form 10-Q are based on current expectations. Forward-looking statements may address the following subjects: results of operations; customer growth and retention; development of technologies; losses or earnings; operating expenses, including, without limitation, marketing expense and technology and development expense; and revenue growth. We caution investors that there can be no assurance that actual results, outcomes or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, among others, our limited operating history, unpredictability of future revenues and operating results, competitive pressures and also the potential risks and uncertainties set forth in the "Overview" section hereof and in the "Overview" and "Risk Factors" sections of our annual report on Form 10-K for the fiscal year ended December 31, 2004 filed with the Securities and Exchange Commission, which factors are specifically incorporated herein by this reference. You should also carefully consider the factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to update any forward-looking statements. 13 PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS - From time to time, we may be involved in litigation relating to claims arising out of our operations in the usual course of business. On September 15, 2004, Third Wave filed suit against Stratagene Corporation in the United States District Court for the Western District of Wisconsin. The complaint alleges patent infringement by Stratagene Corporation of at least several claims in each of the two Third Wave asserted patents concerning the Company's proprietary Invader technology. Discovery is currently underway and trial is scheduled for August 22, 2005. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. (a) None (b) Use of Proceeds. Pursuant to our Registration Statement on Form S-1, as amended, filed with the Securities and Exchange Commission and declared effective February 9, 2001, (Registration No. 333-42694), we commenced our initial public offering of 7,500,000 registered shares of common stock, $0.001 par value, on February 9, 2001, at a price of $11.00 per share (the "Offering"). The Offering was completed on February 14, 2001, and all of the 7,500,000 shares were sold, generating gross proceeds of approximately $82,500,000. The managing underwriters for the Offering were Lehman Brothers Inc., CIBC World Markets, Dain Rauscher Incorporated, Robert W. Baird & Co. Incorporated, and Fidelity Capital Markets. In connection with the Offering, we incurred approximately $5.8 million in underwriting discounts and commissions, and approximately $1.9 million in other related expenses. The net offering proceeds to us, after deducting the foregoing expenses, were approximately $74.8 million. From the time of receipt through March 31, 2005, we have invested the net proceeds from the Offering in investment-grade, interest-bearing securities. We used $4.0 million of the proceeds to satisfy a cancellation fee for the termination of a distribution agreement with Endogen Corporation. We used approximately $14.0 million for general corporate purposes, including working capital and research and development activities. We expect to use the remainder of the net proceeds for general corporate purposes, including working capital and expanding research and development and sales and marketing efforts to accelerate the commercialization of new products and the development of new partnerships. A portion of the net proceeds may also be used to acquire or invest in complementary businesses or products to obtain the right to use complementary technologies. From time to time, in the ordinary course of business, we may evaluate potential acquisitions of these businesses, products, or technologies. We have no current agreements or commitments regarding any such transaction. (c) None ITEM 3. DEFAULTS UPON SENIOR SECURITIES - None. ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS: None ITEM 5. OTHER INFORMATION - None. ITEM 6. EXHIBITS. 14 Exhibits. 10.1 Employment Agreement between Maneesh Arora and Third Wave Technologies, Inc. dated May 10, 2005 10.2 Employment Agreement between Lander R. Brown and Third Wave Technologies, Inc. dated May 10, 2005. 10.3 Employment Agreement between Vecheslav A. Elagin and Third Wave Technologies, Inc. dated May 10, 2005. 10.4 Employment Agreement between Jacob Orville and Third Wave Technologies, Inc. dated May 10, 2005 31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer 31.2 Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer 32 Section 1350 Certifications 15 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. THIRD WAVE TECHNOLOGIES, INC. Date: May 10, 2005 /s/ John Puisis ------------------------------------------- John Puisis, CEO Date: May 10, 2005 /s/ James Herrmann ------------------------------------------- James Herrmann, Principal Financial Officer 16